GH Research (NASDAQ: GHRS) director details initial share and option positions
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
GH Research PLC director Michael Forer reported his initial holdings, consisting of ordinary shares and multiple option grants. He holds 45,509 ordinary shares directly. He also holds fully vested share options over 6,633, 5,508 and 5,532 ordinary shares, each with an exercise price of 0.0250 per share and expirations in 2030 and 2031.
Additional option awards cover 50,000 ordinary shares expiring in 2031 and 4,667 ordinary shares expiring in 2032, also at an exercise price of 0.0250. Some of these options are fully vested and exercisable, while others vest over time or within specified windows under the GH Research PLC Share Option Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Forer Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Options (Right to Buy) — 6,633 shares (Direct);
Ordinary Shares — 45,509 shares (Direct)
Footnotes (1)
- The share options are fully vested and exercisable. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of June 22, 2024. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of July 6, 2024. The share options vested as to 25% on December 9, 2025, and the remaining share options vest in equal monthly installments for three years thereafter. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of September 3, 2025.
Key Figures
Direct ordinary shares held: 45,509 shares
Option grant 1 underlying shares: 6,633 shares
Option grant 2 underlying shares: 5,508 shares
+4 more
7 metrics
Direct ordinary shares held
45,509 shares
Total ordinary shares following reported holdings
Option grant 1 underlying shares
6,633 shares
Share options expiring 2030-09-26
Option grant 2 underlying shares
5,508 shares
Share options expiring 2031-06-22
Option grant 3 underlying shares
5,532 shares
Share options expiring 2031-07-06
Largest option grant underlying shares
50,000 shares
Share options expiring 2031-12-09
Additional option grant shares
4,667 shares
Share options expiring 2032-09-03
Option exercise price
0.0250 per share
Exercise price for all reported option grants
Key Terms
Share Options (Right to Buy), Ordinary Shares, GH Research PLC Share Option Plan, fully vested and exercisable, +1 more
5 terms
fully vested and exercisable financial
"The share options are fully vested and exercisable."
vest in equal monthly installments financial
"the remaining share options vest in equal monthly installments for three years"
FAQ
What did GH Research PLC (GHRS) director Michael Forer report on this Form 3?
He reported his initial ownership in GH Research PLC, including 45,509 ordinary shares held directly and several grants of share options over additional ordinary shares, all at an exercise price of 0.0250 per share with various future expiration dates.